Enhertu recommended in EU for HER2-mutant NSCLC
15 September 2023 Enhertu recommended for approval in the EU by CHMP forpatients with HER2-mutant advanced non-small cell lung cancerRecommendation based on DESTINY-Lung02 trial results which showed AstraZenecaand Daiichi Sankyo's Enhertu achieved strong and durable tumour responses inpreviously treated HER2-mutant disease Enhertu showed a confirmed objective response rate of 49% and median duration ofresponse of 16.8 months AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the